Navigation Links
Cytori breast reconstruction cell therapy trial results published
Date:3/19/2012

Zug, Switzerland and San Diego, CA Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.

RESTORE-2 is a 71 patient multi-center, prospective clinical trial using autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for reconstruction of the breast after cancer surgery. The majority of patients underwent radiation prior to the procedure, creating an unfavorable ischemic environment for which breast reconstruction with ADRC-enriched fat grafting appears to be ideally suited.

Key findings of the trial were:

  • High rates of investigator (85%) and patient (75%) satisfaction with the overall treatment results at 12 months;
  • High rates of investigator (87%) and patient (67%) satisfaction with overall breast deformity (based on functional and cosmetic outcomes) at 12 months;
  • Improved breast contour at both six and 12 months, demonstrated by blinded MRI assessment; and
  • No local cancer recurrences or serious adverse events related to the ADRC-enriched fat grafting procedure.

"Following cancer treatment, the patient's breast tissue can suffer from radiation injury, scarring and tight skin," said Consultant Plastic and Reconstructive Surgeon Mrs. Eva Weiler-Mithoff, co-principal investigator for RESTORE-2 at the NHS Glasgow Royal Infirmary Hospital. "This new technique is exciting because it may offer the opportunity to resolve some of the most difficult to treat conditions where other approaches, including fat alone, do not achieve satisfactory results."

ADRC-enriched partial mastectomy breast reconstruction is marketed in the EU as the RESTORE Procedure and represents an innovative treatment option with significant cost savings potential. The procedure can be performed on an outpatient basis. Satisfactory results can be achieved in a single procedure for the majority of patients. In contrast, competitive approaches are more costly with lengthy hospital stays, require repeat procedures and increase the overall burden on the healthcare system. Furthermore, because of these limitations, physicians are often reluctant to recommend reconstruction for patients with partial mastectomy defects and radiation-induced damage in the breast.

Each year, approximately 450,000 European women are diagnosed with breast cancer. Of the newly diagnosed breast cancer cases, 70-80% are eligible for breast conserving surgery, where only a portion of the breast is removed rather than the full breast. In the European G5, there are an estimated 1.25 million women who have undergone partial mastectomy. The majority of these patients are left with a sizeable volume defect, scarring and often radiation damage.

"Given that there is no widely accepted reconstructive option available today for partial mastectomy patients, this procedure could well address this substantial unmet need and help complete the overall cancer treatment," said Marc H. Hedrick, president of Cytori.


'/>"/>

Contact: Megan McCormick
mmccormick@cytori.com
858-875-5279
Cytori Therapeutics
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Washington, DC (PRWEB) , ... February 11, 2016 ... ... announce an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study ... a not-for-profit Catholic health care system that’s partnering with Intel on value-based health ...
(Date:2/11/2016)... Mount Laurel, NJ (PRWEB) , ... February 11, ... ... Commission) announces the call for nominations seeking candidates for the Board of Commissioners. ... individuals with passion, skills and experience with diversity of clinical practice settings and ...
(Date:2/11/2016)... ... , ... PharmMD CEO Robert Yeager announced today ... contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include healthcare ... breaches for the Part D Star Rating improvement and Medication Therapy Management firm. ...
(Date:2/11/2016)... ... 11, 2016 , ... Greenfield Insurance Group in Orange City, ... the people of their local community. The agency pledges to select a new ... hope is to bring awareness to important local causes with fundraising and other ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... and updated its hallmark resource, Infusion Therapy Standards of Practice, to include vascular ... vein illumination with an estimated 85% share of the market, facilitates adherence to ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... instruments commonly used in laboratories. These may range from ... condensers. Laboratory glassware is made from borosilicate glass because ... Laboratory plasticware, on the other hand, started gaining popularity ... it was easier to replace glass with plastic in ...
(Date:2/11/2016)... Feb. 11, 2016   Health 2.0 , the ... health technologies, announced today " 10 Year Global Retrospective ... tech over the past ten years.   ... decade, Health 2.0 has served as the preeminent thought-leader ... with thousands of technologies, companies, innovators, and patient-activists through ...
(Date:2/11/2016)... , Feb. 11, 2016 AAIPharma Services ... of custom manufacturing and development services for the ... fill-finish capabilities and capacity in its ... demand has driven several recent investments. ... had one filling line with small-scale lyophilization. The ...
Breaking Medicine Technology: